Session Abstract – PMWC 2018 Silicon Valley

Session Synopsis: Interpreting human DNA and predicting the molecular effects of genetic variation will aid in the understanding of human disease and is expected to increasingly provide personalized insights on health risks and recommended disease treatment. The rapid commercialization of AI/machine learning and big data is well positioned to over time change disease diagnosis and management.

Session Chair Profile

Ph.D., CEO, Sema4; Dean for Precision Medicine and the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai
Biography

Eric Schadt was previously Founding Director of the Icahn Institute for Genomics and Multiscale Biology, and Professor and Chair of the Department of Genetics and Genomic Sciences. Dr. Schadt is an expert on constructing predictive models of disease that link molecular biology to physiology to enable clinical medicine. Over the past 20 years, he has built groups and companies (Merck, Rosetta, Sage Bionetworks, Pacific Biosciences, Icahn Institute, and now Sema4) to elucidate the complexity of human diseases. He has published more than 350 peer-reviewed papers in leading scientific journals, and contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease.

Speaker Profile

MPH, M.D., Chief Medical Officer, Verily
Biography

Jessica L. Mega, MD, MPH, is the Chief Medical Officer at Verily Life Sciences. As a faculty member at Harvard Medical School (on leave), a senior investigator with the TIMI Study Group, and a cardiologist at Brigham and Women’s Hospital, she led large, international, randomized trials evaluating novel cardiovascular therapies. She also directed the TIMI Study Group’s Genetics Program. Her research findings have been published in the New England Journal of Medicine, Lancet, JAMA, and elsewhere. Dr. Mega is a graduate of Stanford University, Yale University School of Medicine and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women’s Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology. She has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards, and she is a Fellow of the American Heart Association (AHA) and the American College of Cardiology (ACC).

Speaker Profile

M.D., CEO, InnVentis
Biography

Thomas Wilckensis a medical doctor and entrepreneur. Dr. Wilckens is also the founder of the LinkedIn group Precision Medicine Insight. Prior to InnVentis, he was an associate at deep innovation GmbH. In 1998, he founded a drug discovery company as CEO/CSO with a focus on inflammatory and metabolic diseases. Thomas obtained his MD at the Ludwig-Maximilian University in Munich and started his research career as a scholar of the Max-Planck Society and the Max-Kade Foundation in New York. He held several post-doctorate positions at leading academic institutions before becoming an entrepreneur.Aside from his work in Precision Medicine he developed a novel concept for value creation in research intensive industries; i.e. “Symbiotic Innovation”.

Speaker Profile

Ph.D., CEO & Co-founder, SOPHiA GENETICS
Biography

Dr. Jurgi Camblong is a visionary entrepreneur who is pioneering the Data-Driven Medicine movement around the world. He is a Molecular Biologist (published in Cell, Science & Nature), has a PhD in Life Sciences from the University of Geneva, and an EMBA in Management of Technology from EPFL/HEC Lausanne. In 2011, he founded SOPHiA GENETICS with Dr. Pierre Hutter and Prof. Lars Steinmetz, and has since successfully been leading the development of the company, listed by the MIT Technology Review amongst the 50 smartest companies in 2017. Dr. Camblong is a member of the Advisory Council on Digital Transformation to the Swiss Federal Government, and was personally recognized by EY as Emergent Entrepreneur of the Year in 2017.